Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes. The anti-tumor activity of Olaparib has been largely attributed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tao, Tong, Jing, Wang, Mengxin, Gan, Yu, Gao, Bo, Chen, Jiaxiang, Liu, Youxun, Hao, Qian, Zhou, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204002/
https://www.ncbi.nlm.nih.gov/pubmed/35719981
http://dx.doi.org/10.3389/fonc.2022.821366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204002/
https://www.ncbi.nlm.nih.gov/pubmed/35719981
http://dx.doi.org/10.3389/fonc.2022.821366

Ejemplares similares